|
Variables
|
Total enrolled patients (n = 41)
|
UI-EWD monotherapy (n = 23)
|
|---|
|
Age (year)§
|
74 (39–88)
|
76 (39–88)
|
|
Gender (Male), n (%)
|
31 (75.6)
|
32 (74.4)
|
|
The tumor pathology, n (%)
| | |
|
Adenocarcinoma
|
33 (80.5)
|
17 (73.9)
|
|
Squamous carcinoma
|
2 (4.9)
|
0 (0.0)
|
|
GIST
|
5 (12.2)
|
4 (17.4)
|
|
Lymphoma
|
1 (2.4)
|
2 (8.7)
|
|
Tumor stage, n (%)
| | |
|
1
|
3 (7.3)
|
2 (7.0)
|
|
2
|
2 (4.9)
|
0 (9.3)
|
|
3
|
6 (14.6)
|
3 (16.3)
|
|
4
|
30 (73.2)
|
18 (67.4)
|
|
ASA score, (%)
| | |
|
1
|
2 (4.9)
|
1 (4.3)
|
|
2
|
7 (17.1)
|
4 (17.4)
|
|
3
|
18 (43.9)
|
10 (43.5)
|
|
4
|
13 (31.7)
|
7 (30.4)
|
|
5
|
1 (2.4)
|
1 (4.3)
|
|
Comorbidity, n (%)
| | |
|
HTN
|
18 (43.9)
|
12 (47.8)
|
|
DM
|
12 (29.3)
|
5 (21.7)
|
|
Cardiovascular
|
13 (31.7)
|
7 (30.4)
|
|
CKD
|
4 (9.8)
|
2 (8.7)
|
|
Systolic blood pressure (mmHg)§
|
108 (74–162)
|
108 (74–139)
|
|
Diastolic blood pressure (mmHg)§
|
59 (30–96)
|
59 (30–91)
|
|
Heart rate (per min)§
|
92 (51–177)
|
84 (51–177)
|
|
Hb (g/dL)§
|
6.7 (3.7–14.0)
|
6.7 (3.7–14.0)
|
|
Follow up duration (day) §
|
107 (7–956)
|
57 (7–607)
|
- ASA, American society of anesthesiologist; CKD, chronic kidney disease; DM, diabetes mellitus; GIST, gastrointestinal stromal tumor; Hb, hemoglobin; HTN, hypertension
- §, median (range)
